Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …

In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Protein aggregation is common to dozens of diseases including prionoses, diabetes,
Parkinson's and Alzheimer's. Over the past 15 years, there has been a paradigm shift in …

Alzheimer's disease is increasingly considered a large-scale network disconnection
syndrome, associated with progressive aggregation of pathological proteins, cortical …

Early biomarkers are needed to identify individuals at high risk of preclinical Alzheimer's
disease and to better understand the pathophysiological processes of disease progression …

After advanced age, female sex is the major risk factor for late-onset Alzheimer's disease
(AD), the most common cause of dementia affecting over 24 million people worldwide. The …

Importance Increasing evidence suggests an important role of liver function in the
pathophysiology of Alzheimer disease (AD). The liver is a major metabolic hub; therefore …

Effective and accurate diagnosis of Alzheimer's disease (AD), as well as its prodromal stage
(ie, mild cognitive impairment (MCI)), has attracted more and more attention recently. So far …

Objectives The aim of this article was to review the current role of brain PET in the diagnosis
of Alzheimer dementia. The characteristic patterns of glucose metabolism on brain FDG-PET …